A Twice Daily Posaconazole Dosing Algorithm for Children With Chronic Granulomatous Disease

Welzen, Marieke E.B.; Brüggemann, Roger J. M.; M, van den Berg; Voogt, Heleen W.; Gilissen, Jos H.; Pajkrt, Dasja; Klein, Nigel; Burger, David M.; Warris, Adilia

doi:10.1097/inf.0b013e3182195808

Cited by 45 publications

(45 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Caspofungin and Micafungin are approved for pediatric patients, whereas concerning anidulafungin, there are very little data. Caspofungin, that can only be administered by intravenous route, has been shown to be effective as prophylaxis as well as in the empirical as the therapeutical setting [23][24][25][26]. The drug is approved for children and infants for empirical therapy for neutropenic patients with persistent fever as well as second line antifungal therapy in patients with a proven IA.…”

Section: Treatment and Prophylaxismentioning

confidence: 99%

Invasive Aspergillosis in Children: Where Do We Stand?

M¹

2014

J Infect Dis Ther

View full text Add to dashboard Cite

Invasive opportunistic fungal disease is a well-known complication in immuno deficient patients, adults as well as children. Apart from candida, aspergillus is by far the most common causative agent. Specific guidelines for the pediatric population concerning diagnosis, prophylaxis and treatment of invasive aspergillosis have been published recently and although this has been an important achievement, many challenges remain. This paper gives a short overview of the current guidelines, the recent advances in the diagnosis and management of invasive aspergillosis in the pediatric population. Besides we highlight the unmet needs of the pediatricians who are dealing with patients at risk of this complication.

show abstract

Section: Treatment and Prophylaxismentioning

confidence: 99%

Invasive Aspergillosis in Children: Where Do We Stand?

M¹

2014

J Infect Dis Ther

View full text Add to dashboard Cite

show abstract

“…Dawkowanie leku jest znane dla dzieci >12. roku życia, dla młodszych pacjentów pozostaje ono jednak w sferze hipotez. W Klinice Transplantacji Szpiku, Onkologii i Hematologii Dziecięcej we Wrocławiu stosowano dotychczas 2 schematy dawkowania pozakonazolu u dzieci: 18 mg/kg/d [17] oraz wg zaleceń holenderskich dla dzieci z przewlekłą chorobą ziarniniakową (CGD; chronic granulomatous disease) [18]. Tabela III przedstawia schemat dawkowania zaproponowany przez Welzen i wsp.…”

Section: Praktyka Kliniczna W Polsceunclassified

“…w profilaktyce aspergilozy u dzieci z CGD, stosowany u dzieci ważących min. 10 kg [18]. U prawie wszystkich dzieci uzyskano stężenie leku !0,5 mg/L, rekomendowane przez ECIL-4 i nie obserwowano infekcji z przełamania ani ciężkich objawów ubocznych [18].…”

Section: Praktyka Kliniczna W Polsceunclassified

See 1 more Smart Citation

Profilaktyka zakażeń grzybiczych u dzieci poddawanych transplantacjom komórek hematopoetycznych

Kałwak¹

2014

Acta Haematologica Polonica

View full text Add to dashboard Cite

“…9,10 Prevention of invasive fungal infection using either itraconazole or posaconazole is standard of care in patients with chronic granulomatous disease (CGD). 11,12 The azole antifungal drugs display their activity by targeting lanosterol 14a-demethylase which is involved in ergosterol biosynthesis and is encoded by the cyp51A gene. 13 The resulting depletion of ergosterol leads to altered permeability of the fungal membrane and defective fungal cell wall synthesis.…”

Section: Introductionmentioning

confidence: 99%